-
Mashup Score: 0Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function in Premenopausal Women With Breast Cancer - 2 year(s) ago
This randomized clinical trial examines the effect of administering gonadotropin-releasing hormone analogs during treatment with chemotherapy in premenopausal Chinese women with breast cancer on reducing ovarian impairment.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function in Premenopausal Women With Breast Cancer - 2 year(s) ago
This randomized clinical trial examines the effect of administering gonadotropin-releasing hormone analogs during treatment with chemotherapy in premenopausal Chinese women with breast cancer on reducing ovarian impairment.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function in Premenopausal Women With Breast Cancer - 2 year(s) ago
This randomized clinical trial examines the effect of administering gonadotropin-releasing hormone analogs during treatment with chemotherapy in premenopausal Chinese women with breast cancer on reducing ovarian impairment.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ https://t.co/OUOlIwPSsq
-
-
Mashup Score: 1Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: journals.lww.comCategories: Latest Headlines, OBGYNTweet
-
Mashup Score: 1Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Latest Headlines, OBGYNTweet
-
Mashup Score: 0Haploinsufficiency in non-homologous end joining factor 1 induces ovarian dysfunction in humans and mice - 3 year(s) ago
Background Premature ovarian insufficiency (POI) is a common disease in women that leads to a reduced reproductive lifespan. The aetiology of POI is genetically heterogeneous, with certain double-strand break (DSB) repair genes being implicated in POI. Although non-homologous end joining (NHEJ) is an efficient DSB repair pathway, the functional relationship between this pathway and POI remains…
Source: Journal of Medical GeneticsCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Latest Headlines, OBGYNTweet
-
Mashup Score: 1Registration - 4 year(s) ago
Registration fees to the 2020 NAMS Virtual Annual Meeting will provide participants with 12-month access beginning September 28, 2020, to Plenary Symposia Special Lectures Menopause 101 Course Pre-Meeting Symposium Live Q&A Sessions Virtual Exhibit Hall Abstract Presentations Poster Session Product Theater Registration and CME will be open through September…
Source: www.menopause.orgCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 1
PURPOSE To describe the incidence, relative risk, and risk factors for chronic comorbidities in survivors of adolescent and young adult (AYA) cancer. METHODS This retrospective cohort study included 2-year survivors of AYA cancer diagnosed between age 15 and 39 years at Kaiser Permanente Southern California from 2000 to 2012. A comparison cohort without cancer was individually matched (13:1) to…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/Oyn0DO6OAE https://t.co/lx816RZB50